ABSTRACT The Tn-syndrome is an acquired disorder characterized by the polyagglutination of blood cells and the pathological exposure of a-N-acetyl-D-galactosamine residues (Tn-antigen) at the cell surface. We now report studies on the platelets of a patient (Ba.) of which 81% reacted positively with a fluorescein conjugate of Helix pomatia agglutinin (HPA). The surface proteins of Ba. platelets were labeled with 125I by the lactoperoxidase-catalyzed procedure; single and twodimensional electrophoresis on sodium dodecyl sulfate (SDS)-polyacrylamide gels was followed by autoradiography that revealed normal '251-labeling of the major membrane glycoproteins (GP) but that GP lb had a faster than normal migration. The abnormal GP lb of Ba. platelets was strongly labeled when platelet suspensions were treated sequentially with neuraminidase, galactose oxidase, and sodium [3H]borohydride. Unlike the GP Ib of normal human platelets, it was also strongly labeled when Ba. platelets were treated with galactose oxidase and sodium [3H]borohydride alone. Both the alloantigen, PHAl, and quinidine-dependent antibody receptor activity were normally expressed by Ba. platelets, which also bound a monoclonal antibody (AN51) to GP lb. Analysis of Ba. platelets by crossed immunoelectrophoresis using a rabbit anti-human platelet antibody preparation revealed the presence of an immunoprecipitate in the GP lb position that had an abnormal appearance and migration in the second dimension. An altered position of the precipitate given by Factor VIIIR:Ag was also noted. Incorporation of HPA into the agarose gel during the first dimension electrophoresis resulted in the specific precipitation of the abnormal GP lb of Ba. platelets.
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INTRODUCTION
The Tn-syndrome is a rare pathological state brought about by the exposure of the Tn-antigen on somatic cells. Most early studies described how erythrocytes from Tn-individuals were polyagglutinated by antibodies present in most human sera. Clinically, expression of the Tn-antigen by erythrocytes is of special interest because it is sometimes associated with hemolytic anemia (1, 2) and because it has been described in patients with leukemic and preleukemic states (3) (4) (5) . Several studies have shown that the Tnantigen is expressed following exposure of terminal a-glycosidically linked N-acetyl-D-galactosamine (GalNAc)' residues at the erythrocyte surface (6) (7) (8) . Exposure of GalNAc residues can be detected by binding studies with Helix pomatia agglutinin (HPA), which is specific for both the a-and ,B-anomer of this sugar (9) . Marked alterations in the periodate-Schiff stained patterns were observed following the analysis of membrane glycoproteins (GP) of Tn-erythrocytes by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), with the major sialoglycoprotein (glycophorin A) being particularly decreased in staining intensity (8, 10) . Glycophorin B was also affected (11) . A selective loss in f3-3-D-galactosyltransferase (T-transferase) activity in Tn-erythrocytes suggested that the alkali- ' Abbreviations used in this paper: CBR, Coomassie Brilliant Blue R250; CIE, crossed immunoelectrophoresis; GalNAc, N-acetyl-D-galactosamine; GP, glycoprotein; HPA, Helix pomatia agglutinin; HPA-FITC, HPA-fluorescein isothiocyanate; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TX-100, Triton X-100. labile oligosaccharide chains of the glycophorins were being incompletely synthesized (10, 11) .
Leukocytes and platelets of Tn-individuals have also been shown to be polyagglutinable and a leukopenia and thrombocytopenia is often observed (2, (12) (13) (14) . The frequent association in patients between the exposure of Tn-receptors on erythrocytes and a low platelet count led us to investigate the membrane GP composition of platelets isolated from three Tn-syndrome donors (15) . A modified platelet membrane GP composition was detected with membrane GP lb having a markedly decreased periodate-Schiff staining capacity after SDS-PAGE. Although the abnormality was clearly apparent, it was not determined whether GP lb was absent or structurally modified. The situation was further complicated by the presence of coexisting subpopulations of normal and Tn-positive platelets that varied in proportion between donors (15) . We now describe surface-labeling and other studies performed on the platelets of a patient with >80% Tn-positive platelets. Evidence for the presence of GP Ib with structurally abnormal oligosaccharide chains is provided together with data to suggest that the modified GP Ib is responsible for the platelet expression of Tn-antigen activity.
METHODS
Materials. All materials for SDS-PAGE were of electrophoresis purity grade and were obtained from Bio-Rad Laboratories (Richmond, CA). These included the high and low molecular weight protein standards used for molecular weight determination by SDS-PAGE. Carrier-free Nal25I (100 mCi/ml in NaOH solution, pH [8] [9] [10] [11] Subjects. The patient with Tn-syndrome (Ba.) is a 32-yrold woman whose erythrocytes have been extensively studied (8, 10, 16) . Over 90% of the circulating population of erythrocytes have been shown to be Tn-positive. The patient has been studied by us on four occasions during a period of 3 yr. A low circulating platelet count was consistently observed (Table I) . The patient is a blood group 0 donor, because of this and our extensive use of HPA lectin during the course of our study only donors with blood group 0 activity were selected as controls (see Discussion).
Isolation and washing of platelets. Blood (9 vol) was taken by venepuncture directly into an acid-citrate-dextrose anticoagulant (1 vol) as described previously (17) . The blood was centrifuged at 120 g for 15 min at 15°C to obtain platelet rich plasma. The platelets were washed three times in 10 mM Tris-HCl, 0.15 M NaCl, 1 mM EDTA, pH 7.4 according to the procedures of Nurden et al. (18) .
Immunofluorescent detection of Tn-antigen on platelets. 15 min at 370C after the addition of neuraminidase (1 U/ml in 0.05 M sodium acetate, 0.15 M NaCl, 0.009 M CaCl2, pH 5.5) to a final concentration of 0.1 U enzyme/ml. The digestion was performed in volumes of 1 ml and terminated by the addition of 9 ml 10 mM Tris-HCl, 0.15 M NaCl, 3 mM EDTA, pH 7.4 (Tris-EDTA). The platelets were sedimented by centrifugation at 2,000 g for 10 min and resuspended in 1 ml vol of PBS. These platelets, or suspensions of platelets in PBS that had not been treated with neuraminidase, were incubated with galactose oxidase (10 U/ml, final concentration) for 5 min at 37°C after which each suspension was again made up to 10 ml with Tris-EDTA. The platelets were sedimented, each pellet resuspended in 1 ml PBS, and sodium [3H]borohydride (0.5 mCi) added. The suspensions were left at room temperature for 15 Laemmli (22) buffer systems as we have described previously (18) . Sample volumes contained 100 Mg SDS-solubilized protein. The two-dimensional nonreduced/reduced system of SDS-PAGE (20) was used according to the procedures detailed by Nurden et al. (18) . Briefly, first dimension electrophoresis was performed using 7% acrylamide rod gels and nonreduced samples. Disulphide bond reduction was performed after electrophoresis by incubating the unstained gels in 10 mM Tris-HCl, 1 mM EDTA and 5% vol/vol 2-mercaptoethanol, pH 7.0, for 1 h at room temperature. Second dimension electrophoresis was performed using 0.3-cm thick 7-12% gradient acrylamide slab gels with 3% acrylamide stacking gels as described above, the rod gel being held in position over the stacking gel by a small volume of 1% agarose dissolved in stacking gel buffer. Proteins were detected by Coomassie Brilliant Blue (CBR) staining and '25I-labeled proteins by autoradiography of dried CBR stained gels using Kodak X-omat MA film. 3H-Labeled proteins were located by fluorography. CBR-stained slab gels that had been washed in 7% acetic acid were incubated for 1 h at room temperature with gentle agitation and sufficient EN3HANCE to generously cover the gel. The EN3HANCE was then replaced with an identical volume of cold water and the gel agitated for 1 h to precipitate the scintillator incorporated within the gel. The gel was dried onto filter paper and exposed to Kodak X-omat MA film for up to 3 wk at -70°C.
Crossed immunoelectrophoresis (CIE) . Washed platelets whose surface proteins has been labeled with 125I by the lactoperoxidase-catalyzed procedure, were resuspended at 6 X 109 platelets/ml in 0.038 M Tris-HCl, 0.1 M glycine, pH 8.7 (Tris-glycine). A 1/10 vol of 10% (vol/vol) Triton X-100 (TX-100) prepared in Tris-glycine was added. The suspension was agitated at 4°C for 30 min, then centrifuged at 100,000 g for 1 h at 4°C. CIE of the TX-100 soluble protein was performed at 15°C according to the procedures of Hagen et al. (23, 24) as used by .
Briefly, 100 MAg TX-100 soluble protein was electrophoresed at 10 V/cm for -1 h in first-dimension gels consisting of 1% agarose, 0.5% (vol/vol) TX-100 in Tris-glycine. Electrophoresis in the second dimension was performed at 2 V/cm for 18 h into a biphasic gel system consisting of (a) an intermediate gel containing either 1% agarose, 0.5% (vol/vol) TX-100 in Tris-glycine, or a mixture of monospecific antiserum and the same solution, and (b) an upper gel containing 1% agarose, 0.5% (vol/vol) TX-100 in Tris-glycine and the isolated IgG of a rabbit anti-human platelet serum (800 ,g/ cm2) prepared against washed normal platelets. Details of the immunization procedure and isolation of the IgG by ammonium sulfate precipitation and DEAE-cellulose chromatography have been given elsewhere (23, 25) . The antibody pool used in the present experiments was the same as that used by Kunicki et al. (27) . In certain experiments antihuman Factor VIIIR:Ag serum (50 Ml) or anti-glycocalicin serum (300 Ml) was incorporated into the intermediate gel before the second dimension electrophoresis. In other experiments HPA was incorporated into the first dimension gel at final concentrations of 50 and 20 Ag/ml, respectively.
Antibody binding assays. A well-characterized serum containing quinidine-dependent antibody activity and a second serum containing antibodies reactive with the human platelet alloantigen, P1iA, were selected as previously described (28) . Quinidine-dependent antibody receptor and Pl" antigen activity in Ba. platelets were assayed by the ability of the platelets to inhibit 51Cr-release from normal platelets in the presence of antibody and, for the quinidinedependent antibody, the drug. Techniques for the 5'Cr-labeling of platelets and the assay of antibody reactive sites by inhibition of 51Cr-release were as described by . Briefly, platelets from a member of the hospital staff, previously shown to be homozygous for p1Al, were isolated and labeled with 51Cr for the assay. The 5'Cr-labeled platelets were resuspended at 108/ml in PBS. Test suspensions of washed Ba. platelets and those of a second control donor were prepared at a concentration of 109/ml as described (28) (29) (30) and a series of eight dilutions (see legend to Fig. 5 ) used in the assay. Volumes (20 Ml) of the diluted platelet suspensions were then incubated for 2 h at 37°C in the presence of 20 Ml of a standard dilution of the chosen antiserum. Quinidine sulfate, 1 mM in PBS, was also added at a final concentration of l0' M in the assay for drug-dependent antibody activity. Samples (20 Al) of 5'Cr-labeled platelets and freshly prepared plasma (100 MAl), as a complement source, were then added together with 20 Ml 0.1 M MgCl2, and the incubation continued for a further 2 h at 37°C. At the end of this period the reaction was stopped, the platelets sedimented and the degree of inhibition of platelet lysis determined as previously described (28) (29) (30) . AN 51 is a monoclonal hybridoma antibody against GP Ib, it does not fix complement (31) and therefore could not be used in the above assay. Instead, receptor activity was measured by indirect radioactive binding assay as described by McMichael et al. (31) . Formaldehyde-fixed suspensions of control and Ba. platelets suspended at 109 platelets/ml in PBS, were incubated with serial dilutions of AN51 ascitic fluid or nonimmune mouse serum for 1 h at room temperature. The platelets were twice washed and incubated with '251-labeled (Fab)2 fragments of a rabbit anti-mouse IgG an-tibody for a further 2 h at room temperature. The platelets were again washed and their associated gamma-radioactivity counted in a gamma counter.
Sialic acid determination. Total platelet sialic acid was measured by the thiobarbituric acid method of Aminoff (32) following its release by hydrolysis with 0.1 N H2SO4 at 80°C for 1 h as previously described by us (18) . Results were expressed as micrograms sialic acid/milligram platelet protein, protein being measured by the method of Lowry et al. (33) .
RESULTS
Tn-syndrome platelets. The patient Ba. showed a moderate thrombocytopenia (Table I ) with blood counts of 70-90 X 103/lMl being typical findings over the 3-yr period she has been studied. The protein content of the isolated platelets was in the normal range but the level of sialic acid associated with the platelet protein was markedly reduced. Platelet morphology as studied by standard electron microscopic procedures was normal, no evidence to suggest the presence of an increased proportion of large or giant platelets was obtained (data not shown). The presence of terminal N-acetyl galactosamine residues on the platelet surface was investigated by HPA-labeling with the fluorescein conjugate of the lectin (Fig. 1) platelets (Table II) . Analysis of the protein composition of Ba. platelets by SDS-PAGE followed by CBR-staining revealed a normal polypeptide profile with no evidence of proteolytic degradation of platelet proteins. A faintly stained band (see Fig. 2 ) constituting the upper of a doublet of CBR-staining polypeptides has been previously identified as that being given by GP Ib (18) . This band was absent or displaced on the Ba. platelet profile. Two-dimensional SDS-PAGE analysis. GP lb of normal platelets is a high molecular weight GP composed of two subunit chains linked by one or more disulfide bonds (20, 34) . On disulfide reduction a large a-subunit (Mr 143,000) is separated from a smaller A-subunit (Mr 22,000) (20) . Single dimension electrophoresis of reduced samples of '25I-labeled platelet proteins was performed to see if Ba. platelet GP Iba also migrated faster than normally during SDS-PAGE. However, the close migration of Iba, hIa, Ica, and Ilba after disulfide reduction, prevented an accurate assessment of any mobility change. The nonreduced/reduced two dimensional system of SDS-PAGE of Phillips and Poh Agin (20) gives an improved separation of individual membrane GP. Fig. 3 compares the analysis of '25I-labeled Ba. and normal human platelets by this procedure. It may now be clearly observed that the GP Iba of Ba. platelets had migrated faster relative to IIa and Ilba during the second dimension of the electrophoresis. Other than this change the patterns are comparable, emphasizing the specificity of the GP Ib abnormality of Ba. platelets. GP Ib,B of normal human platelets labels poorly with 1251I during lactoperoxydase-catalyzed iodination (20) and cannot be observed for either normal or Ba. platelets on Fig. 3 FIGURE 3 Two-dimensional SDS-PAGE of the '25I-labeled surface proteins of Ba. and normal human platelets. Washed '251-labeled platelets were solubilized with SDS in the presence of N-ethylmaleimide and samples (100 jig protein) subjected to first dimension electrophoresis using 7% acrylamide rod gels. After electrophoresis, the unstained gels were incubated for 1 h in the presence of 5% 2-mercaptoethanol and second dimension electrophoresis of the now reduced proteins performed on 7-12% gradient slab gels. A single aliquot of reduced '25M-labeled proteins (100 ,ug) of the sample being analyzed was also applied to one side of the slab gel. '251-Labeled proteins were detected on dried gels by autoradiography. A faster migration of GP lb a in the second dimension on the Ba. platelet pattern can be clearly observed by comparing its position relative to Ilb a on both profiles. Note that, as illustrated, the first dimension electrophoresis was from right to left. located in a position perpendicular to Iba on the Ba. profile, it had a normal migration in the second dimension (data not shown).
Labeling with galactose oxidase and sodium [3H]borohydride. Fig. 4 (Table II) showed a 10,000-to 15,000-dalton decrease compared with GP lb of normal platelets. Reduced samples of Ba. platelets were also analyzed. The modified GP Iba was heavily labeled and migrated in a similar position to, or perhaps even slightly faster than, GP lIba (Fig. 4) . GP Fig. 4 . This band was identified by its diminution on the fluorograph after analysis of 'Hlabeled Bernard-Soulier platelets where both a-and ,B-subunits of GP Ib are lacking (35, 36) . GP (43) . The first dimension electrophoresis was from left to right.
Tn-Platelets file. In a similar way to that described above for the antiglycocalicin serum, a monospecific antiserum directed against Factor VIIIR:Ag was incorporated into the intermediate gel during the second dimension electrophoresis. A single immunoprecipitate was precipitated by this antiserum from the Ba. platelet samples (Fig. 6D) . Thus, the immunoprecipitate given by Factor VIIIR:Ag was not absent but displaced on the Ba. platelet pattern. A close examination of Fig. 6B suggests it had migrated further during the second dimension electrophoresis. The strange appearance, and intense staining of the albumin precipitate in Fig. 6D is thought to be due to the cross-reaction of albumin in the antiserum incorporated in the intermediate gel with antialbumin antibodies in the upper gel. This phenomenon was not observed with the antiglycocalicin serum.
Identification of the GP receptor for HPA lectin. Fig. 1 shows that the bulk of Ba. platelets reacted positively with HPA lectin, a known marker for the Tnantigen on 0 group blood cells (see Discussion). In order to identify the membrane GP carrying the HPAlectin receptor, the precedents established in other studies by Hagen et al. (23) and by Shulman and Karpatkin (39) were followed, and the lectin incorporated into the first dimension gel during CIE. Fig. 7A shows that the migration of normal human platelet antigens, and in particular GP Ib, was unchanged by the presence of the lectin. In contrast, the modified GP lb of Ba. platelets was precipitated by the lectin (Fig. 7B) . This was a specific interaction with GP Ib, no other platelet antigens, including Factor VIIIR:Ag, were precipitated by the lectin. This conclusion was also supported when '25I-labeled Ba. platelets were examined. Autoradiography confirmed both the precipitation of GP lb by HPA-lectin, and the normal position r v lb + H P A .p¢ FIGURE 7 Identification of the glycoprotein receptor for HPA in Ba. platelets. CIE of TX-100 soluble extracts of normal human (A) and Ba. platelets (B) was performed as described in the legend to Fig. 6 . HPA (50 ug) was incorporated into the first-dimension gel. Immunoprecipitation patterns in the absence of added lectin were identical to those shown in Fig. 6A (41) . Membrane glycoproteins with an altered oligosaccharide chain composition would be expected to normally incorporate 1251 provided that their structural modifications had not resulted in a reorganization of the molecule in the membrane, thus altering the accessibility of the tyrosine residues to the lactoperoxidase. When Ba. platelets were incubated with 1251, H202, and lactoperoxidase, GP lb was normally labeled but migrated faster on subsequent SDS-PAGE analysis. Ba. platelets were deficient in sialic acid, thus a potential explanation of our finding was that GP lb was smaller due to a sialic acid deficiency. However, previous studies have shown that when normal human platelets are treated with neuraminidase prior to '25i-labeling, the resultant desialated GP Ib migrates more slowly during SDS-PAGE (18, 21) . This apparent anomaly is probably explained by the fact that the anionic charge of sialic acid actually contributes to the migration of GP Ib during SDS-PAGE. The observed faster than normal migration of GP Ib of Ba. platelets therefore suggests a more severe structural alteration of the molecule than a simple sialic acid deficiency.
Unlike that of normal platelets, GP Ib of Ba. platelets labeled strongly when the platelets were incubated with galactose oxidase and sodium [3H]borohydride. Neuraminidase treatment was not a prerequisite for labeling, as it was for the other major membrane GP of Ba. platelets and for all of the membrane GP of normal platelets. This result shows that the abnormal GP Ib of Ba. platelets contains a high proportion of galactose or N-acetylgalactosamine residues in a terminal position on the oligosaccharide chains. Furthermore, analysis of reduced samples following both 125[_ and 3H-labeling procedures suggested that the abnor-mality was confined to the larger, a-subunit of the molecule. It should be emphasized that the Tn-syndrome is the first reported example of a GP defect that is common to both erythrocytes and platelets. Direct analysis of GP extracted from Tn-erythrocytes have shown that the erythrocytes have a low content of sialic acid and galactose (7, 8) . The conclusion from these and other studies is that the chief structural determinant of Tn-specificity in erythrocytes is a glycopeptide containing GalNAc residues a-glycosidically linked to serine and threonine of glycophorin A (for a review see Anstee, 42) . The GalNAc residues are normally substituted to form the disaccharide ,B-D-galactosyl (1-3)-N-GalNAc, the immunodominant group of the Thomsen-Friedenreich antigen (T-antigen). The T-antigen itself is substituted with sialic acid and is present as a sialylated tetrasaccharide attached to the MN-sialoglycoprotein.
Although it is too early to make precise predictions concerning the nature of the oligosaccharide chain composition of platelet GP Iba, certain observations can be made. When platelets are homogenized in Ca21-containing media an endogenous platelet Ca2+-dependent protease degrades GP Ib with the release of a high molecular weight glycopeptide, glycocalicin (43) . Glycocalicin has been purified and characterized (44) . The principal sugars were found to be galactose, Nacetylglucosamine, GalNAc and sialic acid in a ratio (2:1:1:2) with serine and threonine among the most abundant amino acids. The recent studies of Clemetson et al. (34) have shown that there were great similarities between the tryptic peptide maps of asialoglycocalicin and asialo-GP Iba. It appears that the site of action of the Ca2+-dependent protease that cleaves glycocalicin from GP Ib, is not too distant from the disulfides the cleavage of which separates Iba and Ib,B. In all probability, therefore, the oligosaccharide chain composition of GP Iba resembles that of glycocalicin. The presence of the T-antigen exposed on platelet membranes after neuraminidase digestion has been shown (45) . The lectin, peanut agglutinin (Arachis hypogaea) has anti-T specificity (46), binding to terminal galactose residues in glycoproteins. Studies on the binding of 1251-labeled lectins to platelet membrane glycoproteins separated by SDS-PAGE have indicated that peanut agglutinin binds specifically to GP Iba when neuraminidase-treated platelets are being analyzed (34, 47) . These observations collectively suggest a partial similarity between the oligosaccharide chain composition of platelet GP Ib and the MN-sialoglycoprotein of erythrocytes.
When Ba. platelet proteins were analyzed by CIE it was shown that a prominent glycoprotein antigen, that gave rise to an abnormal precipitate located close to the GP Ib position, was specifically precipitated by antiglycocalicin serum. The glycoprotein was also precipitated by HPA and appeared to be the receptor responsible for the strong fluorescence exhibited by the bulk of Ba. platelets on incubation with the FITC-conjugate of the lectin. As discussed earlier, the Tn-specificity is given by terminal GalNAc residues bound to serine or threonine in an alkali-labile 0-glycosidic linkage. This antigen specifically binds Salvia sclarea lectin (46) , however, purified Salvia sclarea lectin was not available to us in the present study and HPA lectin was used. HPA is specific for both the a-and p3-anomers of GalNAc (9) . It is also known that HPA recognizes GalNAc residues associated with blood group A specificity in addition to Tn determinants (2, 9). However, HPA lectin can be safely used in the present studies since our selected patient belongs to the 0 blood group. As an additional precaution only blood group 0 donors were selected as controls. CIE therefore provided additional evidence that Ba. platelets contained GP lb with GalNAc residues in a terminal position on at least some of its oligosaccharide chains.
Platelets of patients with the Bernard-Soulier syndrome lack the receptor for drug-dependent antibodies that is present on the normal platelet surface and which is thought to be given by membrane GP Ib (29, 30) . Ba. platelets normally expressed quinidine-dependent receptor activity thus providing evidence that the antigen is not given by the terminal sugar sequences of the oligosaccharide chains of GP Ib. This finding is in agreement with a previous observation that purified glycocalicin produced no inhibition of quinine-or quinidine-dependent antibody activity (30) . Bernard-Soulier platelets also lack the receptor for the monoclonal hybridoma antibody, AN51, which has been shown to be directed against GP lb by immunoprecipitation reactions (31) . Ba. platelets bound AN51 at levels just below the range for platelets of four control donors. This observation provides strong evidence for the normal presence of at least part of the GP Ib molecule on the Ba. platelet surface. McMichael et al. (31) previously showed that the antibody binding to normal platelets was unaffected by neuraminidase treatment. In the Bernard-Soulier syndrome the lack of GP lb and a low platelet surface sialic acid density is accompanied by the presence of abnormally large platelets in the circulation (see Nurden and Caen, 40) . No such morphological abnormalities were observed on examination of Ba. platelets using standard electron microscopy procedures.
An intriguing finding was the observation of two abnormalities when Ba. platelets were analzyed by CIE. In addition to the abnormal precipitate given by the modified GP Ib, the precipitate given by Factor VIIIR:Ag was also in a different position, having apparently migrated much further into the second di-mension. This suggested either a modified structure of the Factor VIIIR:Ag of Ba. platelets or that the antigen was present in increased concentrations. Further studies will be required to distinguish between these two possibilities. The fact that considerable evidence points to GP lb being the receptor for Factor VIIIR:Ag at the platelet surface (17, 34, 48, 49) suggests that a double abnormality affecting GP lb and Factor VIIIR:Ag in Ba. platelets is not coincidental.
In conclusion, we have presented evidence to show that the majority of the circulating platelets of the patient Ba. contain membrane GP lb with an abnormal oligosaccharide chain structure associated with the presence of terminal GalNAc residues and the expression of the Tn-antigen. This patient is unique among those we have studied in that a large proportion of the circulating platelets are affected. In other patients, coexisting subpopulations of normal and Tn-platelets varied in proportion from donor to donor (15) . The studies that we have reported agree well with the finding of Cartron and Nurden (15) that Tn-platelets have a severely reduced T-transferase activity, the enzyme that adds galactose residues to the C-3 position of alinked GalNAc residues. Thus, GPIb is incompletely synthesized with GalNAc residues remaining in a terminal position. Recent studies have shown that Tndeterminants are also present at the surface of granulocytes as well as platelets and erythrocytes of Tndonors (50) , and that the determinants were present in marrow cells with a clonal expression being observed in colonies formed from blood cell precursors. A somatic mutation affecting the T-transferase enzyme in a pluripotent stem cell may well be the origin of the defect. Studies are continuing to characterize the platelet GP lb defect in the Tn-syndrome, the possible relationship between the abnormality and the low circulating platelet count, and the effect of the defect on platelet function.
